Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3).

作者
Markus Moehler,Gunnar Folprecht,Volker Heinemann,Julian Walter Holch,Annett Maderer,Stefan Kasper,Susanna Hegewisch-Becker,Jan Schröder,Friedrich Overkamp,Frank Kullmann,Wolf O. Bechstein,Matthias Vöhringer,Robert Öllinger,Florian Lordick,Michael Geißler,Armin Schulz-Abelius,Bernhard Linz,Helga Bernhard,Andreas Paul,Irene Schmidtmann,Karin Potthoff,Carl C. Schimanski
出处
期刊:International Journal of Cancer [Wiley]
标识
DOI:10.1002/ijc.33881
摘要

Metastatic colorectal cancer (mCRC) patients with liver-limited disease (LLD) have a chance of long-term survival and potential cure after hepatic metastasectomy. However, the appropriate postoperative treatment strategy is still controversial. The CELIM and FIRE-3 studies demonstrated that secondary hepatic resection significantly improved overall survival. The objective of this analysis was to compare these favorable outcome data with recent results from the LICC trial investigating the antigen-specific cancer vaccine tecemotide (L-BLP-25) as adjuvant therapy in mCRC patients with LLD after R0/R1 resection. Data from mCRC patients with LLD and secondary hepatic resection from each study were analyzed for efficacy outcomes based on patient characteristics, treatment and surveillance after surgery. In LICC, 40/121 (33%) patients, in CELIM 36/111 (32%) and in FIRE-3-LLD 29/133 (22%) patients were secondarily resected, respectively. Of those, 31 (77.5%) patients in LICC and all patients in CELIM were R0 resected. Median disease-free survival after resection was 8.9 months in LICC, 9.9 months in CELIM. Median overall survival in secondarily resected patients was 66.1 months in LICC, 53.9 months in CELIM and 56.2 months in FIRE-3-LLD. Median age was about 5 years less in LICC compared to CELIM and FIRE-3. Secondarily resected patients of LICC, CELIM and FIRE-3 showed an impressive median survival with a tendency for improved survival for patients in the LICC trial. A younger patient cohort but also more selective surgery, improved resection techniques, deep responses and a close surveillance program after surgery in the LICC trial may have had a positive impact on survival. This article is protected by copyright. All rights reserved.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
酷波er应助廿伊采纳,获得30
刚刚
2秒前
张宝完成签到,获得积分10
4秒前
薄雪草完成签到,获得积分10
7秒前
大橙子发布了新的文献求助10
7秒前
快乐学习每一天完成签到 ,获得积分10
7秒前
薄荷味完成签到 ,获得积分0
9秒前
科研通AI2S应助笑林采纳,获得10
9秒前
无心的雅旋完成签到,获得积分10
10秒前
量子星尘发布了新的文献求助10
11秒前
Horizon完成签到 ,获得积分10
15秒前
Oliver完成签到 ,获得积分10
17秒前
Superman完成签到 ,获得积分10
20秒前
Tina酱完成签到 ,获得积分10
20秒前
琪琪完成签到,获得积分10
20秒前
双碳小王子完成签到,获得积分10
22秒前
smottom应助科研通管家采纳,获得10
24秒前
24秒前
明时完成签到,获得积分10
25秒前
杨瑞东完成签到 ,获得积分10
28秒前
yyyy完成签到,获得积分10
36秒前
缥缈的平卉完成签到 ,获得积分10
37秒前
量子星尘发布了新的文献求助10
48秒前
李爱国应助大橙子采纳,获得10
49秒前
magictoo发布了新的文献求助30
55秒前
57秒前
yang完成签到,获得积分10
57秒前
Minicoper发布了新的文献求助10
58秒前
快乐丸子完成签到,获得积分10
59秒前
简单而复杂完成签到,获得积分10
59秒前
大橙子发布了新的文献求助10
1分钟前
张牧之完成签到 ,获得积分10
1分钟前
冷冷暴力完成签到,获得积分10
1分钟前
YYY完成签到,获得积分10
1分钟前
1分钟前
gujian完成签到 ,获得积分10
1分钟前
帅气的秘密完成签到 ,获得积分10
1分钟前
自然函发布了新的文献求助10
1分钟前
冰冰双双完成签到,获得积分10
1分钟前
开心夏旋完成签到 ,获得积分0
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038128
求助须知:如何正确求助?哪些是违规求助? 3575831
关于积分的说明 11373827
捐赠科研通 3305610
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022